retatrutide parkinson's disease clinical trial Help cure Parkinson's disease: please don't waste the Golden Year Retatrutide Provides Substantial Weight Loss

In a 2025 preclinical study in rats, intranasal administration of semaglutide using MetP Pharmas technology resulted in brain-to-plasma ratios consistently greater than 1, confirming preferential delivery to the central nervous system (CNS)

discard expired or unused medication as directed by your healthcare provider or pharmacist

That background matters when youre trusting someone with your metabolic health

GLP-1 medications are not appropriate for people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2), a history of pancreatitis, severe gastrointestinal disease, or active eating disorders, and are not used during pregnancy or breastfeeding